Meta-analyse van de effectiviteit van celiprolol bij astma

Chronic obstructive pulmonary diseases and asthma are contraindications for the use of β-receptor-blocking agents because of their bronchoconstrictive effect. Despite this effect, however, these compounds are frequently used in these conditions since in some respects they are superior to other cardiovascular compounds in the treatment of hypertension and angina pectoris. It is claimed that celiprolol, a β-receptor-blocking agent of the third generation, has no deleterious effects on lungfunction. A meta-analysis (thirteen studies) was performed to compare the effects of celiprolol with placebo, selective and nonselective β-receptor-blocking agents on the forced expiratory volume within 1 second in patients with asthma. The weighted mean (95% confidence interval) of the difference in change in the forced expiratory volume within 1 second between celiprolol 200 mg on the one hand and placebo, selective and non-selective β-receptor-blocking agents on the other hand were 3.0% (-2.8-8.8%), 13.8% (5.6-22.0%) and 25.6% (19.1-32.1%). These values were 5.2% (-0.1-10.5%), 21.6% (14.7-28.5%) and 28.9% (22.3-35.5%), respectively, for the 400 mg dose. Celiprolol is the first β-receptor-blocking agent that does not cause bronchoconstriction shortly after its administration in patients with asthma.